Full Breakdown
Pfizer's Q3 2025 Earnings Report: A Mixed Outlook Amid Declining COVID Revenues
11/4/2025, 8:23:17 PM
Key Financial Highlights
Pfizer Inc. (NYSE: PFE) reported its third-quarter earnings for 2025, revealing adjusted earnings per share (EPS) of 87 cents, surpassing analysts' expectations of 63 cents. However, this figure represents a decline from $1.06 in the same quarter last year. The company's revenue for the quarter was $16.65 billion, a 6% decrease year-over-year, although it slightly exceeded the consensus estimate of $16.59 billion. Pfizer maintained its full-year revenue guidance between $61 billion and $64 billion, reflecting ongoing challenges in the COVID-19 product market.
Impact of COVID-19 Product Sales
The decline in revenue was primarily attributed to reduced demand for COVID-19 products, including the vaccine Comirnaty and the antiviral pill Paxlovid. Sales of Comirnaty fell 20% to $1.15 billion, while Paxlovid revenues plummeted 55% to $1.23 billion due to lower infection rates and a narrower vaccination recommendation in the U.S. Conversely, sales from core drugs such as the heart medication Vyndaqel and the blood thinner Eliquis showed resilience, with Vyndaqel sales increasing by 7% to $1.59 billion and Eliquis rising 22% to approximately $2.02 billion.
Cost-Cutting Measures and Future Guidance
Pfizer's management announced a plan to cut costs by $7.7 billion by the end of 2027, with $4.5 billion targeted for completion by the end of 2025. This initiative is part of a broader strategy to enhance operational efficiency amid declining revenues from COVID-related products. The company raised its full-year adjusted profit guidance to a range of $3.00 to $3.15 per share, up from previous estimates of $2.90 to $3.10, indicating a cautious optimism about its non-COVID drug portfolio.
Official Statements & Responses
Pfizer's CFO, Dave Denton, stated, “Our performance continues to exceed expectations and deliver strong results, even as the incidence of COVID remains low.” He also highlighted the company's commitment to investing $70 billion in U.S. manufacturing and research facilities, which is expected to help stabilize drug prices for American patients.
Criticism & Opposition
Despite the positive adjustments in guidance, some analysts expressed concerns regarding Pfizer's reliance on its non-COVID drug portfolio to offset losses from pandemic-related products. The company has faced scrutiny over its declining operational revenue, which has raised questions about its long-term growth prospects.
Conflicting Reports & Gaps
While Pfizer's adjusted EPS beat expectations, the overall sentiment remains mixed due to the significant year-over-year decline in revenue. Analysts project a potential revenue decline of 2% over the next 12 months, contrasting with the company's optimistic outlook.
Verbatim Quotes
- “What I can say is that our belief in the promise of the Pfizer and Metsera combination is strong and unwavering,” — Albert Bourla, CEO of Pfizer.
- “We believe that Novo Nordisk's offer is illusory, and cannot constitute a superior proposal under the terms of our merger agreement with Metsera because it violates antitrust law and there is a high risk it will never be consummated,” — Albert Bourla, CEO of Pfizer.
In summary, Pfizer's Q3 2025 earnings report reflects a complex landscape where strong performance in non-COVID drugs is overshadowed by declining revenues from pandemic-related products. The company's proactive cost-cutting measures and adjusted profit guidance suggest a strategic pivot towards sustainable growth amidst ongoing market challenges.
